Русские видео

Сейчас в тренде

Иностранные видео




Если кнопки скачивания не загрузились НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием, пожалуйста напишите в поддержку по адресу внизу страницы.
Спасибо за использование сервиса ClipSaver.ru



Should BTKi therapy be discontinued in CLL?

Kerry Rogers, MD, Ohio State University, Columbus, OH, advocates for the continuous use of BTK inhibitors (BTKis) in chronic lymphocytic leukemia (CLL), highlighting evidence which demonstrates that years of prolonged exposure to these agents is likely necessary to reduce the disease burden and maximize the response in patients. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Comments